Document is current
Any future updates will be listed below
-
Authors
Israel, Justus Simon
Marcelin, Laura-Maria
Thomas, Christian
Szczyrbová, Eva
Fuessel, Susanne
Puhr, Martin
Linxweiler, Johannes
Yalala, Shivani
Zwart, Wilbert T.
Baniahmad, Aria
van Goubergen, Jasper
Itkonen, Harri M.
Sharp, Adam
O’Neill, Edward
Pretze, Marc
Miederer, Matthias
Erb, Holger H.H. https://orcid.org/0000-0001-5209-7914
- License Information
-
More Information
Article History
Received: 15 June 2024
Accepted: 11 July 2024
First Online: 17 July 2024
Declarations
:
: Not applicable.
: Not applicable.
: A.S. is an employee of the ICR, which has a commercial interest in abiraterone, PARP inhibition in DNA repair defective cancers, and PI3K/AKT pathway inhibitors (no personal income). A.S. has received travel support from Sanofi, Roche-Genentech and Nurix, and speaker honoraria from Astellas Pharma and Merck Sharp & Dohme. He has served as an advisor to DE Shaw Research, CHARM Therapeutics, Ellipses Pharma and Droia Ventures. A.S. has been the CI/PI of industry-sponsored clinical trials.
